• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 3 Health Care Stocks That Are Ticking Portfolio Bombs

    3/14/24 8:57:27 AM ET
    $APGE
    $CBAY
    $MOH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGE alert in real time by email

    As of March 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

    The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

    Here’s the latest list of major overbought players in this sector.

    Molina Healthcare, Inc. (NYSE:MOH)

    • On March 6, Barclays analyst Andrew Mok initiated coverage on Molina Healthcare with an Equal-Weight rating and announced a price target of $437. The company’s stock gained around 3% over the past five days and has a 52-week high of $410.00 .
    • RSI Value: 88.79
    • MOH Price Action: Shares of Molina Healthcare gained 0.6% to close at $404.89 on Wednesday.

    Apogee Therapeutics, Inc. (NASDAQ:APGE)

    • On March 7, Apogee Therapeutics priced upsized $420 million underwritten public offering of 6,774,193 common shares at $62 per share. The company’s stock gained around 99% over the past month and has a 52-week high of $72.29.
    • RSI Value: 86.76
    • APGE Price Action: Shares of Apogee Therapeutics gained 0.7% to close at $69.80 on Wednesday.

    CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

    • On Feb. 28, CymaBay Therapeutics posted a wider-than-expected quarterly loss. The company’s stock gained around 1% over the past five days has a 52-week high of $32.47.
    • RSI Value: 80.88
    • CBAY Price Action: Shares of CymaBay Therapeutics closed at $32.44 on Wednesday.

     

    Read More: HP, Cisco And 2 Other Stocks Insiders Are Selling

    Get the next $APGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGE
    $CBAY
    $MOH

    CompanyDatePrice TargetRatingAnalyst
    Apogee Therapeutics Inc.
    $APGE
    3/18/2026$83.00Hold
    Truist
    Molina Healthcare Inc
    $MOH
    2/20/2026$141.00Overweight → Equal Weight
    Wells Fargo
    Apogee Therapeutics Inc.
    $APGE
    1/22/2026$83.00Outperform → Sector Perform
    RBC Capital Mkts
    Apogee Therapeutics Inc.
    $APGE
    1/7/2026Peer Perform
    Wolfe Research
    Apogee Therapeutics Inc.
    $APGE
    12/17/2025$95.00Overweight
    Stephens
    Apogee Therapeutics Inc.
    $APGE
    12/10/2025$103.00Buy
    Deutsche Bank
    Apogee Therapeutics Inc.
    $APGE
    11/3/2025$109.00Buy
    Craig Hallum
    Molina Healthcare Inc
    $MOH
    10/24/2025$144.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $APGE
    $CBAY
    $MOH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Henderson Michael Thomas sold $1,495,605 worth of shares (20,000 units at $74.78), decreasing direct ownership by 2% to 1,152,987 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    3/13/26 8:00:08 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Romney Ronna sold $74,342 worth of shares (506 units at $146.92) (SEC Form 4)

    4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

    3/13/26 4:36:09 PM ET
    $MOH
    Medical Specialities
    Health Care

    Chief Medical Officer Dambkowski Carl exercised 4,125 shares at a strike of $22.86 and sold $390,825 worth of shares (5,500 units at $71.06), decreasing direct ownership by 0.65% to 209,773 units (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    3/6/26 8:00:10 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $CBAY
    $MOH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zoretic Richard C bought $100,128 worth of shares (800 units at $125.16) (SEC Form 4)

    4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

    2/12/26 8:27:47 PM ET
    $MOH
    Medical Specialities
    Health Care

    Chief Operating Officer Woys James bought $1,559,365 worth of shares (10,000 units at $155.94), increasing direct ownership by 16% to 74,331 units (SEC Form 4)

    4 - MOLINA HEALTHCARE, INC. (0001179929) (Issuer)

    8/6/25 4:47:39 PM ET
    $MOH
    Medical Specialities
    Health Care

    Director Mckenna Mark C. bought $990,775 worth of shares (20,000 units at $49.54) (SEC Form 4)

    4 - Apogee Therapeutics, Inc. (0001974640) (Issuer)

    12/16/24 6:00:10 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $CBAY
    $MOH
    SEC Filings

    View All

    SEC Form PRE 14A filed by Molina Healthcare Inc

    PRE 14A - MOLINA HEALTHCARE, INC. (0001179929) (Filer)

    3/13/26 4:24:22 PM ET
    $MOH
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Apogee Therapeutics Inc.

    SCHEDULE 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

    3/6/26 12:57:46 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Apogee Therapeutics Inc.

    S-8 - Apogee Therapeutics, Inc. (0001974640) (Filer)

    3/2/26 7:32:44 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $CBAY
    $MOH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIVDELZI issued to CYMABAY THERAPEUTICS INC

    Submission status for CYMABAY THERAPEUTICS INC's drug LIVDELZI (ORIG-1) with active ingredient SELADELPAR has changed to 'Approval' on 08/14/2024. Application Category: NDA, Application Number: 217899, Application Classification: Type 1 - New Molecular Entity

    8/14/24 12:53:53 PM ET
    $CBAY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGE
    $CBAY
    $MOH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Apogee Therapeutics with a new price target

    Truist initiated coverage of Apogee Therapeutics with a rating of Hold and set a new price target of $83.00

    3/18/26 8:22:50 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molina Healthcare downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Molina Healthcare from Overweight to Equal Weight and set a new price target of $141.00

    2/20/26 8:22:16 AM ET
    $MOH
    Medical Specialities
    Health Care

    Apogee Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Apogee Therapeutics from Outperform to Sector Perform and set a new price target of $83.00

    1/22/26 8:24:52 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $CBAY
    $MOH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

    Zumilokibart (APG777) trials continue to advance in atopic dermatitis (AD) with plans for expansion indications underway:- APEX Phase 2 Part A 52-week data expected this month- APEX Phase 2 Part B 16-week data expected in Q2 2026- Phase 3 trial initiation in AD anticipated in 2H 2026- Successful expansion of zumilokibart beyond AD demonstrated in asthma Phase 1b trial; details on asthma and eosinophilic esophagitis (EoE) trials expected later this year Phase 1b head-to-head trial of APG279 (zumilokibart + APG990) vs. DUPIXENT underway, with interim AD data anticipated in 2H 2026 Strong total cash position of $902.9 million with runway into 2H 2028 supports advancement toward potential laun

    3/2/26 7:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Molina Healthcare Announces First Quarter 2026 Earnings Release and Conferences Call Dates and Investor Day Meeting

    Molina Healthcare, Inc. (NYSE:MOH) ("Molina" or the "Company") today announced it will issue its earnings release for the first quarter ending March 31, 2026, after the market closes on Wednesday, April 22, 2026, and will host a conference call and webcast to discuss the earnings release on Thursday, April 23, 2026, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 4352622. A telephonic replay of the conference call will be available through Thursday, April 30, 2026, by dialing (855) 669-9658 and entering the confirmation number, 6456388. A live broadcast of Molina Healthcare's conference call will be available on

    2/26/26 4:15:00 PM ET
    $MOH
    Medical Specialities
    Health Care

    $APGE
    $CBAY
    $MOH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Apogee Therapeutics Inc.

    SC 13G/A - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 5:46:11 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Molina Healthcare Inc

    SC 13G/A - MOLINA HEALTHCARE, INC. (0001179929) (Subject)

    11/14/24 1:22:34 PM ET
    $MOH
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Apogee Therapeutics Inc.

    SC 13G - Apogee Therapeutics, Inc. (0001974640) (Subject)

    11/14/24 11:16:12 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $CBAY
    $MOH
    Leadership Updates

    Live Leadership Updates

    View All

    Vertiv Holdings, Lumentum Holdings, Coherent, and EchoStar Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600

    NEW YORK, March 6, 2026 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices: NAPCO Security Technologies Inc. (NASD: NSSC) will replace Alexander & Baldwin Inc. (NYSE:ALEX) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, March 13. An investor group comprised of MW Group and funds affiliated with DivcoWest and Blackstone Real Estate is acquiring Alexander & Baldwin in a deal that is expected to close soon, pending final closing conditions.The following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 will take effect before the market opens on M

    3/6/26 6:39:00 PM ET
    $AGX
    $AHRT
    $AIG
    Engineering & Construction
    Consumer Discretionary
    Real Estate
    Finance

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apogee Therapeutics Announces Agenda for Virtual R&D Day

    SAN FRANCISCO and WALTHAM, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (NASDAQ:APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced the agenda for its upcoming virtual R&D Day being held on Monday, December 2, 2024 at 10:00 a.m. ET. Featured Speakers:Members of the Apogee management team will be joined by key opinion leaders (KOLs) who will discuss the current landscape and need for new t

    11/29/24 1:00:00 PM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APGE
    $CBAY
    $MOH
    Financials

    Live finance-specific insights

    View All

    Molina Healthcare Announces First Quarter 2026 Earnings Release and Conferences Call Dates and Investor Day Meeting

    Molina Healthcare, Inc. (NYSE:MOH) ("Molina" or the "Company") today announced it will issue its earnings release for the first quarter ending March 31, 2026, after the market closes on Wednesday, April 22, 2026, and will host a conference call and webcast to discuss the earnings release on Thursday, April 23, 2026, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 4352622. A telephonic replay of the conference call will be available through Thursday, April 30, 2026, by dialing (855) 669-9658 and entering the confirmation number, 6456388. A live broadcast of Molina Healthcare's conference call will be available on

    2/26/26 4:15:00 PM ET
    $MOH
    Medical Specialities
    Health Care

    Molina Healthcare Reports Fourth Quarter and Year-End 2025 Financial Results

    Introduces Full Year 2026 Revenue and Earnings Guidance Molina Healthcare, Inc. (NYSE:MOH) (the "Company") today reported fourth quarter 2025 GAAP loss per diluted share of $3.15 and adjusted loss per diluted share of $2.75. The Company also reported full year 2025 GAAP earnings per diluted share of $8.92 and adjusted earnings per diluted share of $11.03. Financial results are summarized below:   Three months ended   Year ended   December 31,   December 31,   2025   2024   2025   2024                 (In millions, except per-share resu

    2/5/26 4:15:00 PM ET
    $MOH
    Medical Specialities
    Health Care

    Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook

    Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression of FeNO through 32 weeks for patients with available follow up - Results reinforce continued development in asthma testing every 3- or 6-month dosing Successful expansion of zumilokibart beyond dermatology confirms its pipeline-in-a-product potential across I&I indications Zumilokibart in atopic dermatitis (AD) advancing in Phase 2 APEX trials with goal of Phase 3 initiation by end of 2026:- Part A maintenance (52-week) data readout expected in Q1 2026 with potential to establish best-in-class e

    1/6/26 6:00:00 AM ET
    $APGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care